SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 10, 2020
CHINA JO-JO DRUGSTORES, INC.
(Exact name of Registrant as specified in charter)
or other jurisdiction
|(Commission File No.)||(IRS
Hai Wai Hai Tongxin Mansion Floor 6 Gong Shu District,
Hangzhou City, Zhejiang Province, People’s Republic of China, 310008
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: +86-571-88219579
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|Trading Symbol(s)||Name of each exchange on which registered|
|Common Stock||CJJD||NASDAQ Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On July 10, 2020, China Jo-Jo Drugstores, Inc. (the “Company”) issued a press release announcing certain financial results for the fiscal year ended March 31, 2020. A copy of the press release is attached hereto as Exhibit 99.1.
This information under this Item 2.02 and the press release attached to this Form 8-K as Exhibit 99.1 shall be deemed to be “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended.
Item 9.01. Financial Statements and Exhibits.
The following is filed as an exhibit to this report:
|99.1||Press Release, dated July 10, 2020.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CHINA JO-JO DRUGSTORES, INC.|
|Date: July 10, 2020||By:||/s/ Ming Zhao|
|Title:||Chief Financial Officer|
China Jo-Jo Drugstores Reports Fiscal Year 2020 Financial Results
HANGZHOU, China, July 10, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) (“Jo-Jo Drugstores” or the “Company”), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the fiscal year ended March 31, 2020.
Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, “We are pleased to present our financial results for our 2020 fiscal year. Our revenue records $117.33 million for the fiscal year of 2020, up 9.1% compared to $107.55 million for the previous fiscal year. Revenue from retail drugstores, online pharmacy, and wholesale segments increased by 2.4%, 54.1% and 12.4% respectively, demonstrating our ability to realize the potential of our business model. When facing the pandemic of COVID-19, we are uniquely positioned to understand consumer and market needs and how to address them. We will continue monitoring the latest developments and taking appropriate measures to combat the COVID-19 pandemic and provide supports to our customers and the society. Looking forward, we are confident that we are on the right track to deliver significant value to all our investors and shareholders as we have a leading consumer brand in China with a diversified portfolio of essential health care businesses and we will continue to endeavor to provide the best experience to our customers.”
Fiscal Year 2020 Financial Highlights
|For the Year Ended March 31,|
|($ millions, except per share data)||2020||2019||% Change|
|Gross margin||21.8||%||23.3||%||-1.5 pp||*|
|Loss from operations||(7.00||)||(0.88||)||-699.4||%|
|Loss per share||(0.18||)||(0.03||)||-500.0||%|
*Notes: pp represents percentage points
|●||Revenue increased by 9.1% to $117.33 million for the fiscal year ended March 31, 2020 from $107.55 million for the prior fiscal year.|
|●||Gross profit increased by 1.7% to $25.53 million for the fiscal year ended March 31, 2020 from $25.11 million for the prior fiscal year.|
|●||Gross margin decreased by 1.5 percentage points to 21.8% for the fiscal year ended March 31, 2020 from 23.3% for the prior fiscal year.|
|●||Net loss was $6.46 million, or $0.18 per basic and diluted share, for the fiscal year ended March 31, 2020, compared to net loss of $1.32 million, or $0.03 per basic and diluted share, for the prior fiscal year.|
Fiscal Year 2020 Financial Results
Revenue for the fiscal year ended March 31, 2020 increased by $9.78 million, or 9.1%, to $117.33 million from $107.55 million for the prior fiscal year. The increase in revenue was primarily due to the growth in retail drugstores, online pharmacy and wholesale business.
|For the Year Ended March 31,|
|($ millions)||Revenue||Cost of Goods||Gross Margin||Revenue||Cost of Goods||Gross Margin|
Revenue from the retail drugstores business increased by $1.74 million, or 2.4%, to $74.08 million for the fiscal year ended March 31, 2020 from $72.34 million for the prior fiscal year. The increase was primarily attributable to the consumer-facing benefits, such as on-site medical care, chronic disease management services, incremental DTP (Direct-to-Patient) business caused by continuous hospital medical reform, and maturing of stores opened a year ago.
Revenue from the online pharmacy business increased by $4.76 million, or 54.1%, to $13.54 million for the fiscal year ended March 31, 2020 from $8.78 million for the prior fiscal year. The increase was caused by an increase in sales via e-commerce platforms such as Tmall and an increase in sales via our official site. Popular products at reasonable prices are key to success in online business. In order to promote the Company’s sales, the Company focused on the selection of medical equipment suitable to local customers. Additionally, we maintained a membership care program targeted at chronic disease customers. We have closely interacted with our members via WeChat by providing healthcare knowledge and reminding our customers to refill medicine. By implementing a personalized customer care program, we were able to promote our sales. As a result, our sales via these e-commerce platforms increased by 58.3% period over period. The sales via our official website were primarily made by certain pharmacy benefit management providers and insurance companies. For example, we have signed a service contract with Yingda Taihe Life Insurance Co. Ltd. (“Yingda”), a national insurance company. State Grid Corporation of China has bought health insurance package for its employees from Yingda. In the year ended March 31, 2020, we served a local factory of State Grid and sold healthcare products to its employees who used their insurance cards to make payments. The sales from these customers contributed significantly to our official website sales. Additionally, in the first quarter of calendar 2020, during the outbreak of COVID-19, we sold a large quantity of health protective products such as masks. Our official website sales increased by $847,899 or 40.8% year over year.
Revenue from the wholesale business increased by $3.28 million, or 12.4%, to $29.71 million for the fiscal year ended March 31, 2020 from $26.43 million for the prior fiscal year. The increase was primarily a result of the Company’s ability to resell certain products, which the Company sold in large quantities at its retail stores, to other vendors at competitive prices.
Gross profit and gross margin
Total cost of goods sold increased by $9.36 million, or 11.4%, to $91.80 million for the fiscal year ended March 31, 2020 from $82.44 million for the prior fiscal year. Gross profit increased by $0.42 million, or 1.7%, to $25.53 million for fiscal year ended March 31, 2020 from $25.11 million for the prior fiscal year. Overall gross margin decreased by 1.5 percentage points to 21.8% for the fiscal year ended March 31, 2020, from 23.3% for the prior fiscal year.
Gross margins for retail drugstores, online pharmacy and wholesale were 28.1%, 10.6%, and 11.0%, respectively, for the fiscal year ended March 31, 2020, compared to the corresponding gross margins of 29.2%, 11.8%, and 11.3% for the prior fiscal year.
Loss from operations
Selling and marketing expenses decreased by $0.48 million, or 1.9%, to $23.79 million for the fiscal year ended March 31, 2020 from $24.27 million for the prior fiscal year, primarily due to decrease in rent. As we closed several stores, rent expense went down. Additionally, we have closely monitored our marketing expense such as small gifts. As a result, our sale and marketing expense declined slightly.
General and administrative expenses increased by $6.39 million, or 371.7%, to $8.11 million for the fiscal year ended March 31, 2020 from $1.72 million for the prior fiscal year. In the year ended March 31, 2020, we recorded bad debt expense of $455,159 as compared to a reduction in the allowance for bad debts of $3,346,886 in fiscal year 2019. Additionally, we incurred additional labor cost of approximately $1.5 million as we have expanded certain business. For example, we have been operating two Linjia Clinics and hired more doctors. In addition, in order to obtain business from commercial health insurance providers, we formed a marketing team. Although these businesses have not contributed significantly to our revenue, they incurred labor costs.
Impairment of long-lived assets was $0.63 million for the fiscal year ended March 31, 2020, compared to nil for the prior fiscal year. In the year ended March 31, 2020, we evaluated the licenses of insurance applicable drugstores acquired in the past based on their discounted positive cash value. Due to the stricter government insurance policy in fiscal year 2021, the value of these licenses has declined.
Loss from operations was $7.00 million for the fiscal year ended March 31, 2020, compared to loss from operations of $0.88 million for the prior fiscal year. Operating margin was (6.0)% and (0.8)% for the fiscal year ended March 31, 2020 and 2019 respectively.
Net loss was $6.46 million, or $0.18 per basic and diluted share for the fiscal year ended March 31, 2020, compared to net loss of $1.32 million, or $0.03 per basic and diluted share for the prior fiscal year.
As of March 31, 2020, the Company had cash of $16.18 million, compared to $9.32 million as of March 31, 2019. Net cash used in operating activities was $6.91 million for the fiscal year ended March 31, 2020, compared to $5.60 million for the prior fiscal year. Net cash used in investing activities was $4.84 million for the fiscal year ended March 31, 2020, compared to $7.33 million for the prior fiscal year. Net cash provided by financing activities was $19.01 million for the fiscal year ended March 31, 2020, compared to $8.08 million for the prior fiscal year. On April 15, 2019, we closed a registered direct offering of 4,000,008 shares of common stock at $2.50 per share with gross proceeds of $10,000,020 from our effective shelf registration statement on Form S-3. In addition, on June 3, 2020, we closed another registered direct offering of 5,000,0004 shares of common stock at $2.00 per share with gross proceeds of $10,000,008 from our effective shelf registration statement on Form S-3.
About China Jo-Jo Drugstores, Inc.
China Jo-Jo Drugstores, Inc. (“Jo-Jo Drugstores” or the “Company”), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. In addition, Jo-Jo Drugstores cultivates herbs used for traditional Chinese medicine. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.
This press release contains information about the Company’s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company’s encourages you to review other factors that may affect its future results in the Company’s annual reports and in its other filings with the Securities and Exchange Commission.
For more information, please contact:
Chief Financial Officer
Investor Relations Director
Investor Relations Contact:
Ascent Investor Relations LLC
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
|March 31,||March 31,|
|Cash and cash equivalents||$||16,176,318||$||9,322,463|
|Financial assets available for sale||157,159||180,928|
|Trade accounts receivable||9,770,656||8,692,514|
|Other receivables, net||5,069,442||4,438,230|
|Advances to suppliers||1,174,800||1,950,252|
|Other current assets||1,528,540||2,063,375|
|Total current assets||60,987,212||56,202,981|
|PROPERTY AND EQUIPMENT, net||7,633,740||8,727,358|
|Long term deposits||1,456,384||2,157,275|
|Other noncurrent assets||1,046,763||1,196,197|
|Operating lease right-of-use assets||21,711,376||-|
|Intangible assets, net||3,393,960||3,597,323|
|Total other assets||30,895,281||7,800,297|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Short-term bank loan||1,410,130||-|
|Accounts payable, trade||21,559,494||23,106,230|
|Other payables - related parties||490,218||795,179|
|Long-term loan payable-current portion||2,287,742||-|
|Current portion of operating lease liabilities||981,090||-|
|Total current liabilities||57,437,974||55,212,286|
|Long-term loan payable||4,115,958||-|
|Long term operating lease liabilities||19,049,575||-|
|Purchase option and warrants liability||64,090||465,248|
|COMMITMENTS AND CONTINGENCIES|
|Common stock; $0.001 par value; 250,000,000 shares authorized; 32,936,786 and 28,936,778 shares issued and outstanding as of March 31, 2020 and March 31, 2019||32,937||28,937|
|Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2020 and March 31, 2019||-||-|
|Additional paid-in capital||54,209,301||44,905,664|
|Accumulated other comprehensive income||1,440,424||2,508,964|
|Total stockholders’ equity||20,590,934||18,165,206|
|Total liabilities and stockholders’ equity||$||99,516,233||$||72,730,636|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
|For the years ended|
|COST OF GOODS SOLD||91,801,259||82,442,969|
|GENERAL AND ADMINISTRATIVE EXPENSES||8,108,377||1,718,989|
|IMPAIRMENT OF LONG-LIVED ASSETS||628,192||-|
|TOTAL OPERATING EXPENSES||32,530,172||25,984,173|
|LOSS FROM OPERATIONS||(7,003,742||)||(876,130||)|
|OTHER INCOME (EXPENSE):|
|CHANGE IN FAIR VALUE OF PURCHASE OPTION AND WARRANTS LIABILITY||401,158||(326,452||)|
|LOSS BEFORE INCOME TAXES||(6,441,419||)||(1,183,006||)|
|PROVISION FOR INCOME TAXES||16,258||134,763|
|ADD: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST||(644,308||)||(391,491||)|
|NET LOSS ATTRIBUTABLE TO CHINA JO-JO DRUGSTORES, INC.||(5,813,369||)||(926,278||)|
|OTHER COMPREHENSIVE LOSS|
|FOREIGN CURRENCY TRANSLATION ADJUSTMENTS||(1,068,540||)||(1,077,496||)|
|WEIGHTED AVERAGE NUMBER OF SHARES:|
|LOSS PER SHARES:|
CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
|For the years ended|
|CASH FLOWS FROM OPERATING ACTIVITIES:|
|Adjustments to reconcile net income to net cash used in operating activities:|
|Bad debt direct write-off and provision||446,354||(3,357,851||)|
|Depreciation and amortization||2,082,817||1,676,413|
|Impairment of long lived assets||628,192||-|
|Stock based compensation||34,560||197,100|
|Change in fair value of purchase option derivative liability||(401,158||)||326,452|
|Change in operating assets:|
|Accounts receivable, trade||(1,567,774||)||(116,810||)|
|Inventories and biological assets||979,935||(1,390,823||)|
|Advances to suppliers||148,638||3,612,453|
|Long term deposit||596,209||183,841|
|Other current assets||(1,278,833||)||(83,372||)|
|Other noncurrent assets||87,065||(23,511||)|
|Change in operating liabilities:|
|Accounts payable, trade||(317,755||)||(528,353||)|
|Other payables and accrued liabilities||(967,751||)||(328,473||)|
|Net cash used in operating activities||(6,907,945||)||(5,603,216||)|
|CASH FLOWS FROM INVESTING ACTIVITIES:|
|Disposal of financial assets available for sale||14,356||87,290|
|Purchase of financial assets available for sale||-||(104,360||)|
|Acquisition of equipment and building||(656,297||)||(5,450,934||)|
|Investment in a joint venture||(2,567,083||)||-|
|Increase intangible assets||(871,145||)||(29,817||)|
|Additions to leasehold improvements||(756,444||)||(1,828,360||)|
|Net cash used in investing activities||(4,836,613||)||(7,326,181||)|
|CASH FLOWS FROM FINANCING ACTIVITIES:|
|Proceeds from short-term bank loan||1,435,620||-|
|Proceeds from third parties loan||7,178,100||-|
|Repayment of third parties loan||(658,645||)||-|
|Proceeds from notes payable||48,974,772||42,030,521|
|Repayment of notes payable||(46,896,917||)||(34,018,811||)|
|Increase in financial liability||(7,178||)||81,997|
|Proceeds from sale of stock and warrants||9,273,077||7,529|
|Repayment of other payables-related parties||(285,123||)||(22,655||)|
|Net cash provided by financing activities||19,013,706||8,078,581|
|EFFECT OF EXCHANGE RATE ON CASH||(1,031,744||)||(1,856,174||)|
|INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH||6,237,404||(6,706,989||)|
|CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year||24,745,202||31,452,191|
|CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year||$||30,982,606||$||24,745,202|
|SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:|
|Cash paid for income taxes||$||17,198||$||56,422|
|Cash paid for interest||108,098||-|